NCT01227551View on ClinicalTrials.gov

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 29, 2011

Primary Completion Date

April 6, 2016

Study Completion Date

April 6, 2016

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

Coxsackievirus A21 (CVA21)

CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.

Trial Locations (10)

33140

Mount Sinai Medical Center, Miami Beach

46260

Investigative Clinical Research of Indiana, Indianapolis

60612

Rush University Medical Center, Chicago

60714

Oncology Specialists, SC, Niles

75201

Mary Crowley Cancer Research Centers, Dallas

84112

Huntsman Cancer Institute, Salt Lake City

92093

Moores UCSD Cancer Center, La Jolla

94117

St Mary's Medical Center, San Francisco

97213

Providence Cancer Center, Portland

07962

Atlantic Melanoma Center, Morristown

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT01227551 - A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) | Biotech Hunter | Biotech Hunter